Immuno-Oncology Drugs Market 2024-2033: Competitor Assessment, Industry Size And Major Players

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033

The Business Research Company offers in-depth market insights through Immuno-Oncology Drugs Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The immuno-oncology drugs market size has grown rapidly in recent years. It will grow from $92.78 billion in 2023 to $105.64 billion in 2024 at a compound annual growth rate (CAGR) of 13.9%. The growth in the historic period can be attributed to rise in the number of cancer cases, strong economic growth in emerging markets, increased healthcare expenditure, and an increase in pharmaceutical r&d expenditure. the market was restrained by high cost of immuno-oncology therapies, low healthcare access, pricing pressures from regulators, high r&d costs, and patent expiration of drugs..

The immuno-oncology drugs market size is expected to see rapid growth in the next few years. It will grow to $175.05 billion in 2028 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to increasing investment in immuno-oncology, rising focus on immunotherapy drugs for cancer treatment, product innovations through strategic collaborations and increasing geriatric population are expected to drive the market. . Major trends in the forecast period include companies should develop microneedle injector-based drugs to increase the bioavailability and eliminate side effects of the subcutaneous route, consider investing in developing personalized oncology drugs to treat specific patients, consider investing in acquisitions to increase market shares and expand their product portfolio offerings, focus efforts on the development of next-generation biologics to increase revenue and market share, focus on the development of antibody-drug conjugates to manufacture medicines for cancer treatment, invest in ai solutions, reduce r&d costs and save development time, invest in 3d printing devices to test new oncology drugs, opt for immune-oncology combination therapies to boost innovation and establish category leadership, and implement car-t therapies to boost innovations and establish category leadership..

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=3455&type=smp

Market Segmentation:
The immuno-oncology drugs market covered in this report is segmented -
1) By Type: Immune Checkpoint Inhibitors, Immune System Modulators, Other Monoclonal Antibodies, Cancer Vaccines, Others
2) By Therapeutic Application: Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer, Other Therapeutic Application
3) By End-Users: Hospitals, Clinics, Ambulatory Surgical Centers, Others

Major Driver - Global Surge In Cancer Cases And Its Effect On The Market
The rise in the number of cancer cases across the globe is likely to contribute to the growth of the immuno-oncology drugs market. For instance, in January 2022, according to the American Cancer Society, there will likely be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, or roughly 1,670 fatalities every day. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all new cancer cases. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of new cancer cases. Therefore, the rise in cancer incidence rates globally is anticipated to boost demand for the immune-oncology drugs market over the coming years.

Competitive Landscape:
Major companies operating in the immuno-oncology drugs market report are F. Hoffmann-La Roche Ltd., Merck & Co., Bristol-Myers Squibb Company, Amgen Inc, Johnson & Johnson, AstraZeneca Plc, Eli Lilly and Company, Novartis International AG, Pfizer Inc., Sanofi S.A., Arlak Biotech, Healthkind Labs Pvt. Ltd., SwisscheM Healthcare Pvt.Ltd, Apikos Pharma, Kolaz biotech, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Takeda Pharmaceuticals, Astellas Pharma Inc, Otsuka Pharmaceutical Co, Ltd, Legend Biotech Co, Zai Lab, Daiichi Pharmaceutical and Sankyo, AQVIDA GmbH, Baxter International Inc., GlaxoSmithKline plc, Affimed Therapeutics, Autolus Therapeutics, Cellectis, Celyad, GammaDelta Therapeutics, Immunocore, European Medical Center (EMC), Yauza Medical Center, Celon Pharma, Veropharm, Biocad, Selvita, OncoArendi Therapeutics Mabion, Fate Therapeutics, Forty-Seven, Arcus Biosciences, Gritstone Oncology, Rakuten Medical, Rubius Therapeutics, Allogene Therapeutics, Celgene Corporation, Bayer AG, Incyte Corporation, Recepta Biopharma, CSC Pharmaceuticals International, Blanver EN, Sandoz Brazil, Life Pharma, Julphar, NewBridge Pharmaceuticals, Eurolab

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/immuno-oncology-drug-global-market-report

Top Trend - Collaboration In The Immuno-Oncology Drugs Market
Companies in the immuno-oncology drugs market are increasing their product innovation through strategic collaborations. To sustain themselves in the increasingly competitive immuno-oncology drugs market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with academic and research institutions in this market by way of partnerships and in- or out-licensing deals, this trend has been increasing over the past few years. For instance, in September 2021, Boehringer Ingelheim, a Germany-based pharmaceutical company and OSE Immunotherapeutics, a France-based biotechnology company announced a collaboration and license agreement to develop a novel checkpoint inhibitor for the treatment of advanced solid tumors.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Immuno-Oncology Drugs Market Characteristics
3. Immuno-Oncology Drugs Market Trends And Strategies
4. Immuno-Oncology Drugs Market - Macro Economic Scenario
5. Immuno-Oncology Drugs Market Size And Growth
…..
27. Immuno-Oncology Drugs Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.